Tuesday, September 29, 2015
Cloud Pharmaceuticals, a cloud-based drug design and development company located in Research Triangle Park, N.C., and Switzerland-based THERAMetrics have formed a strategic collaboration focusing on the design and development of therapeutics for orphan central nervous system (CNS) diseases and other indications.
Intarcia Therapeutics has announced the acquisition of Phoundry Pharmaceuticals, a privately held biotechnology company based in Research Triangle Park, N.C. Founded in 2015 after six years of work as part of the Enteroendocrine Discovery Performance Unit of GlaxoSmithKline, Phoundry Pharmaceuticals has created a portfolio of optimized peptides in various therapeutic categories, most notably diabetes and obesity.
Novartis has launched Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for $1 per treatment, per month.
Clinigen Group, a specialty global pharmaceutical company, has agreed to acquire Link Healthcare, a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia (AAA) region, for an initial consideration of $67.9 million and a maximum of approximately $152.5 million based on achievement of milestones.
Following the economic and legal separation of Covestro, Bayer is charting the course for its successful development as a life science company. From Jan. 1, 2016, the company’s business will be managed by three divisions: Pharmaceuticals, Consumer Health and Crop Science. The present structure of a strategic management holding company and operational subgroups will be replaced by an integrated organization under the umbrella of the strong Bayer brand.
Nanomed co-founders Ross Bundy and Dr. Brett Goldsmith have launched Nanomedical Diagnostics, a San Diego-based biotech company developing and commercializing bioelectronics for use in research and diagnostics. Nanomed’s first product, AGILE Research, a label-free, quantitative, low-cost biosensor for small molecule and protein analysis, is entering beta testing this fall and planned for commercial release in early 2016.